The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood pla...

FIELD: medicine pharmaceutics. ^ SUBSTANCE: invention relates to medicine namely to field of sanitary and hygiene and deals with means for oral cavity care. Claimed therapeutic and proh[phylactic paste contains dicalcium phosphate dihydrate aerosil sodium carboxymethylcellulose sodium salt of methylparaben sodium salt of propylparaben sorbitol sodium lauryl sulfate perfluorodecalin allantoin sodium monofluorophosphate sodium pyrophosphate potassium pyrophosphate metronidazole calcium glycerophos...

PROBLEM TO BE SOLVED: To provide a simple method for producing a fenofibrate-containing pharmaceutical preparation composition having solubility and absorbability comparable to those of a pharmaceutical preparation containing a surfactant without containing sodium lauryl sulfate or a nonionic surfactant in the fenofibrate-containing pharmaceutical preparation composition.SOLUTION: The method is characterized by producing granules containing micronized fenofibrate and a water-soluble polymer by w...

The invention is related to the use of a composition of fenofibrate containing micronized fenofibrate a surfactant and a binding cellulose derivative as a solubilization adjuvant said composition containing an amount of fenofibrate greater than or equal to 60% by weight for the preparation of a medicament for treating hypertriglyceridemias hypercholesterolemias or hyperlipidemias while reducing the food effect on the bioävailability of fenofibrate. The invention is also related to an immediate r...

The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmo1/L; the oral dosage form produces an pregnane metabolites mean blood pla...

A pesticide composition and method of eliminating pests combines water and a solid form of sodium lauryl sulfate to form a pesticide composition effective to cause mortality in pests. The pesticide composition is applied to the indoor structure in an area which the pests inhabit. The sodium lauryl sulfate can be in needle form pellet form or powder form and constitutes between about 1% and about 10% by weight of the pesticide composition. The pesticide composition may be applied to an area inhab...

The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood pla...

The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood pla...

Disclosed herein is a pharmaceutical composition in the form of a tablet which; (a) comprises 300 mg or 400 mg of nevirapine in an extended release matrix and which when administered as a single-dose to a fasting human wherein the extended release matrix comprises a hydrophilic polymer selected from hydroxypropylmethylcellulose (HPMC hypromellose) hydroxypropylcellulose (HPC) hydroxyethylcellulose (HEC) xanthan gum sodium alginate polyethylene oxide and crosslinked homopolymers and copolymers of...